MISSION VIEJO, Calif., July 19, 2017 (GLOBE NEWSWIRE) -- MYnd Analytics, Inc. (NASDAQ:MYND), a predictive analytics company which brings objective physical findings to psychiatric treatment in order to reduce trial and error prescribing, today announced the closing of its underwritten public offering of 1,675,000 shares of its common stock and warrants to purchase up to 1,675,000 shares of its common stock at a combined public offering price of $5.25 per share and accompanying warrant for gross proceeds of $8,793,750, before deducting underwriting discounts, commissions and estimated offering expenses payable by MYnd. The warrants are exercisable immediately, will expire five years from the date of issuance and have an exercise price of $5.25 per share, subject to adjustment. Following the pricing of the public offering, MYnd's common stock and warrants commenced trading on the NASDAQ Capital Market trading under the symbols "MYND" and "MYNDW", respectively.
In addition, MYnd has granted the underwriters a 45-day option to purchase up to 251,250 additional shares of common stock and/or additional warrants to purchase up to 251,250 shares of common stock solely to cover over-allotments, if any, at the public offering price per share and per warrant, less underwriting discounts and commissions.
Maxim Group LLC and Aegis Capital Corp. acted as joint book-running managers, and R.F. Lafferty & Co., Inc. acted as co-manager for the offering.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on July 13, 2017. When available, copies of the final prospectus relating to this offering may be obtained from Maxim Group LLC, 405 Lexington Avenue, 2nd Floor, New York, NY 10174 or via telephone at 212-895-3745. The final prospectus relating to the offering will also be available on the SEC's website at http://www.sec.gov. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About MYnd Analytics, Inc.
MYnd Analytics, Inc. (www.myndanalytics.com) is a predictive medicine company which brings objective physical findings to psychiatric treatment in order to reduce trial and error prescribing. The Company’s Psychiatric EEG Evaluation Registry, or PEER Online®, is a registry and reporting platform that allows medical professionals to exchange treatment outcome data for patients referenced to objective neurophysiology data obtained through a standard electroencephalogram (EEG). Based on the Company’s original physician developed database, there are now more than 38,000 outcomes for over 10,000 unique patients in the PEER registry. The goal of PEER Online® is to provide objective, personalized data to assist physicians in the selection of appropriate medications.
To read more about the benefits of this patented technology for patients, physicians and payers, please visit www.myndanalytics.com.
Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements are generally statements that can be identified by the words "anticipate," "believe," "estimate," "expect," "intend," "goal," "may," "might," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors. These risks and uncertainties include, without limitation, that the volatility of our stock price may prevent shares purchased in the offering from being resold at or above the price paid for them, purchasers of shares in the offering will suffer immediate and substantial dilution, that we may use the proceeds from the offering in ways that may not enhance our operating results or the market price of our common stock, that the health care industry will not embrace our tools or accept our service as providing a benefit or lowering costs, that we will be unable to announce any milestones and other risks and uncertainties which are discussed in more detail in our Annual Report on Form 10-K for the year ended September 30, 2016, filed on December 22, 2016, and our other reports filed with the Securities and Exchange Commission. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.
Source:MYnd Analytics, Inc.